RNA-seq of cardiomyocytes exposed to glucose deprivation with or without empagliflozin treatment
Ontology highlight
ABSTRACT: Glucose-lowering drugs sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of serious heart failure events, regardless of diabetes status, but the underling mechanism of this cardioprotective benefit is unknown. Here, we performed RNA-seq screening in cardiomyocytes to determine the potential cardioprotective mechanism of empagliflozin (EMPA).
ORGANISM(S): Rattus norvegicus
PROVIDER: GSE200598 | GEO | 2022/12/12
REPOSITORIES: GEO
ACCESS DATA